![]() Individuals may also experience anemia, which can result in end-organ damage and premature death. People with SCD can experience painful blood vessel blockages, also known as vaso-occlusive crises (VOCs), that can lead to acute chest syndrome, stroke, jaundice and symptoms of heart failure. SCD causes severe pain, organ damage and shortened life span due to misshapen or “sickled” blood cells. Sickle cell disease (SCD) is an inherited blood disorder that affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. In the U.K., exa-cel was granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA, and Vertex is already working closely with national health authorities to secure access for eligible patients as quickly as possible. ![]() “This authorization offers a new option for eligible patients who are waiting for innovative therapies, and I look forward to patients having access to this therapy as quickly as possible,” said Professor Josu de la Fuente, Principal Investigator in the CLIMB-111 and CLIMB-121 studies, Professor of Practice (Cellular & Gene Therapy) at Imperial College London, and Consultant Haematologist at Imperial College Healthcare NHS Trust. The safety profile of 97 SCD and TDT patients treated to date with CASGEVY in these ongoing studies is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant. Once achieved, these benefits are potentially expected to be life-long. In two global clinical trials of CASGEVY in SCD and TDT, the trials met their respective primary outcome of becoming free from severe VOCs or transfusion independent for at least 12 consecutive months. “I hope this represents the first of many applications of this Nobel Prize winning technology to benefit eligible patients with serious diseases,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics.” “Today is a historic day in science and medicine: this authorization of CASGEVY in Great Britain is the first regulatory authorization of a CRISPR-based therapy in the world,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. There are an estimated 2,000 patients eligible for CASGEVY in the U.K. Cindy Hollenbeck, who has extensive experience in respiratory diseases as well as natural remedies and, 2) the Global Wellness Institute, a non-profit organization with a mission to empower wellness worldwide by educating the public and private sectors about preventative health and wellness.Īlso, now that we also provide Infrared Therapy as part of our new HaloIR product, we would also recommend that you visit our Benefits of Infrared page Here.BOSTON & ZUG, Switzerland-( BUSINESS WIRE)- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel ), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).ĬASGEVY has been authorized for the treatment of eligible patients 12 years of age and older with SCD with recurrent vaso-occlusive crises (VOCs) or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. If you would like access to research on halotherapy we would recommend that you visit the following resources: 1) The World Halotherapy Association – an independent organization run by Dr. Below is a cross-section of research in each area of halotherapy’s key benefits to getting a start on the subject. Halotherapy Solutions’ equipment was designed in Estonia, one of the original locations for this early halotherapy.ĭue to this history, much of the research on halotherapy has taken place in Eastern Europe but is now starting to get more attention in other areas of the world such as the United States and Australia. Later entrepreneurs built machines to replicate this environment and modern halotherapy was born. These doctors then began to “prescribe” visits to the salt mines and at some point the mines even carved out separate areas for this original halotherapy (see photo). ![]() ![]() Halotherapy was originally “discovered” in the 1800s in Eastern Europe when doctors realized that salt miners didn’t suffer nearly as often from respiratory and skin conditions as others in the communities. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |